Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections

Phase 3RecruitingNCT04832607

Tobias Feuchtinger149 enrolled

Overview

Haematopoietic stem cell transplantation (HSCT) can expose patients to a transient but marked immunosuppression, during which viral infections are an important cause of morbidity and mortality. Adoptive transfer of virus-specific T cells is an attractive approach to restore protective T-cell immunity in patients with refractory viral infections after allogeneic HSCT. The aim of this Phase III trial is to confirm efficacy of this treatment in children and adults.

For a growing number of patients suffering from various conditions as, e.g., haematological malignancies or diverse genetic disorders, haematopoietic stem cell transplantation (HSCT) or bone marrow transplantation offer the only possible curative options. However, HSCT is associated with three major risks: graft rejection, graft-versus-host disease (GvHD) and opportunistic, mostly viral, infections or reactivations resulting from delayed immune reconstitution. Delayed immune reconstitution, however, often is the direct result of the severe pre-transplantation conditioning treatment and T-cell depletion of the transplant necessary to fight the risks of graft rejection and GvHD. Therefore, the risk for life-threatening opportunistic, mostly viral, infections is increased in post-transplantation patients. The most common infections after HSCT are Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Adenovirus (AdV). The standard treatment approach for viral infections/reactivations is chemotherapy which shows limited efficacy and does not restore immunity. Therefore, effective new treatment options are required for this condition. Previous investigations have shown that sufficient T-cell immunity is essential for the control and prevention of viral reactivations and newly occurring infections after HSCT. The infusion of T-cells is therefore a promising new approach to treat immune-comprised patients. However, infusion with unselected T cells is associated with an increased risk for GvHD due to the high content of alloreactive T cells. A very promising approach to minimize this problem is to remove alloreactive T cells and enrich, isolate and purify virus-specific T cells. This approach has been studied for nearly two decades and the data published up to date indicate that virus-specific T-cell responses after adoptive T-cell transfer protect against virus-related complications post HSCT and restore T-cell immunity, in particular for AdV-, CMV- and EBV-infections. Despite these promising results, virus-specific T-cell transfer is not yet translated into daily clinical practice due to the lack of prospective clinical trials confirming the efficacy of this treatment approach. The overall goal of this Phase III, double-blind placebo-controlled study is to test efficacy of multivirus-specific T cells to bring this treatment method in clinical routine. Multivirus-specific T cells generated in this study will be directed against all three most common post-HSCT viral infections: AdV, CMV and EBV. Thus, T-cell immunity will be restored to fight and prevent new viral infections. After an initial screening visit, patients eligible to participate in the study will be treated within 28 days after screening. Patients will be randomized in a 2:1 (treatment: placebo) ratio and receive a single infusion with either multivirus-specific T cells or placebo. Patients will be followed up on the day of treatment, 1 day after and 1, 2, 4, 8 and 15 weeks after treatment. Treatment success will be measured by assessing different parameters including symptoms, quality of life, viral load and T-cell immunity in blood samples. Patients eligible to participate in this study are adult and paediatric patients who have received allogeneic stem cell transplantation and suffer from new or reactivated EBV, AdV or CMV infection refractory to standard antiviral treatment for two weeks. Patients from the six European countries Germany, Belgium, Netherlands, UK, France and Italy will be enrolled. In total 130 patients plus 19 screening failures are expected to participate in the study.

Eligibility

Sex: ALLMin age: 2 Months

Medical Language ↔ Plain English

Inclusion Criteria: 1. Adult or paediatric patients (\> 2 months of age) after allogeneic stem cell transplantation (SCT) (no time restrictions apply) suffering from new or reactivated CMV or EBV or AdV infection refractory to standard antiviral treatment for two weeks (defined as no decrease or insignificant decrease of less than 1log in viral load over two weeks) as confirmed by quantitative blood PCR analysis. 2. Original HSCT-donor available with an immune response at least to the virus causing the therapy-refractory (=underlying) infection. 3. Written informed consent given (patient or legal representative) prior to any study-related procedures. Exclusion Criteria: 1. Patient with acute GvHD \> grade II or extensive chronic GvHD at the time of IMP transfer 2. Patient receiving steroids (\>1 mg/kg BW Prednisone equivalent) at Screening. 3. Therapeutic donor lymphocyte infusion (DLI) from 4 weeks prior to IMP infusion until 8 weeks post IMP infusion. Prescheduled prophylactic DLI ≤3x105 T cells/kg BW in case of T-cell depleted HSCT is not considered an exclusion criterion. 4. Patient with organ dysfunction or failure as determined by Karnofsky (patients \>16 years) or Lansky (patients ≤16 years) score ≤30% 5. Concomitant enrolment in another clinical trial interfering with the endpoints of this study 6. Any medical condition which could compromise participation in the study according to the investigator's assessment 7. Progression of underlying disease (disease that has led to the indication of HSCT, e.g. leukaemia) that will limit the life expectance below the duration of the study 8. Second line or experimental antiviral treatment other than Ganciclovir/Valganciclovir, Foscarnet, Cidofovir and Rituximab until 8 weeks after IMP Infusion or prophylactic Treatment other than Aciclovir or Letermovir throughout the study except approved by sponsor 9. Known HIV infection. In case patients do not have a negative HIV test performed within 6 months before enrolment in the study, HIV negativity has to be confirmed by a negative laboratory test. 10. Female patient who is pregnant or breast-feeding. Female patient of child-bearing potential (i.e. post menarche and not surgically sterilized) or male patient of reproductive potential not willing to use an effective method of birth control from Screening until the last follow-up visit (FU6, Visit 8). Note: Women of childbearing potential must have a negative serum pregnancy test at study entry ≤7 days before IMP administration on Day 0. Acceptable birth control methods are hormonal oral contraceptive ('pill'), contraceptive injection or patch, intrauterine pessar or the combination of two barrier methods. The combination of female and male condomes is NOT acceptable. If the male partner is sterilized, no further contraceptive is required. Women of post-menopausal status (no menses for 12 months without an alternative medical cause) are also not required to use contraceptives during the study. 11. Known hypersensitivity to iron dextran 12. Patients unwilling or unable to comply with the protocol or unable to give informed consent.

Outcomes

Primary Outcomes

Viral clearance

Percentage of patients with viral clearance (defined as two consecutive negative PCRs) to determine efficacy of multispecific T-cell transfer in patients with chemo-refractory viral infections after allogeneic stem cell transplantation

Time frame: 8 weeks after treatment

Disease Progression

Percentage of patients with progression between Day 7 and Week 8 after T-cell Transfer to determine efficacy of multispecific T-cell transfer in patients with chemo-refractory viral infections after allogeneic stem cell transplantation

Time frame: day 7 until week 8 after treatment

Secondary Outcomes

Incidence of acute GvHD

Incidence of newly occurring acute GvHD grade I from Day 0 to Week 8 and Week 15.

Time frame: 15 weeks after treatment

Incidence of chronic GvHD

Incidence of chronic GvHD from Day 7 to Week 8 and to Week 15 after treatment.

Time frame: 15 weeks after treatment

Time to newly occuring GvHD

Time to newly occurring acute and chronic GvHD.

Time frame: 15 weeks after treatment

Severity of GvHD

Severity of acute GvHD ≥ grade II until Week 8 and Week 15.

Time frame: week 8 and 15 week after treatment

Incidence of acute toxicity

Acute maximum toxicity on the day of T-cell transfer evaluated by measuring vital signs prior to and at different times after the T-cell transfer from 1 hour prior to T-cell transfer to 4 hours post infusion.

Time frame: 15 minutes, 30 minutes, 2 hours and 4 hours post T-cell/placebo transfer

Severity of acute toxicity

Monitoring of adverse events infusion.

Time frame: 15 minutes, 30 minutes, 2 hours and 4 hours post T-cell/placebo transfer

Change in viral load of underlying viral infection

Change in viral load of underlying viral infection as assessed by quantitative PCR analysis of peripheral blood; samples taken weekly from Day 7 to Week 8 after IMP transfer as compared to samples taken at Day 0.

Time frame: 8 weeks after treatment

Time to viral load change of underlying viral infection

Time to 1 log change in viral load.

Time frame: 15 weeks after treatment

Percentage of viral decrease

Percentage of patients with ≥1 log decrease in CMV, EBV or AdV viral load at Week 8.

Time frame: 8 weeks after treatment

Viral reactivations

Number of reactivations of the underlying viral infection following initial viral clearance until end of follow-up.

Time frame: 15 weeks after treatment

Clinical response/resolution of symptoms of underlying viral infection

Number of patients with reduction or clearance of clinical symptoms of underlyingviral infection from Day 7 to Week 8 after IMP transfer as compared to Day 0.

Time frame: 8 weeks after treatment

Overall survival

Overall survival rate (OS): From Day 0 to end of follow-up.

Time frame: 15 weeks after treatment

Necessity of antiviral chemotherapy

Number of days requiring antiviral chemotherapy after T-cell transfer from Day 7 to Week 8 after T-cell transfer.

Time frame: Day 7 until Week 8

Duration of antiviral chemotherapy

Time to last administration of defined antiviral medication or switch to prophylactic treatment from Day 0 to Week 8 after IMP transfer.

Time frame: 8 weeks after treatment

Incidence of viral infections other than underlying viral infection

Number of new viral reactivations (CMV, AdV or EBV) other than the underlying viral infection per patient as assessed by PCR analysis and clinical symptoms throughout the study to evaluate the putative prophylactic effect of the treatment.

Time frame: 15 weeks

Days of hospitalization

Number of days hospitalized after IMP transfer from Day 7 to Week 8.

Time frame: 8 weeks

Life quality in adults

EQ-5D for adult patients (≥18 years) at Screening and Week 8 to evaluate life quality in adults. A scale from 0 to 100 is used with 100 being best value and 0 the worst.

Time frame: Screening and Week 8.

Life quality in adults

FACT-BMT for adult patients (≥18 years) at Screening and Week 8 to evaluate life quality in adults. The patients have to answer questions about their physicial, social, emotional and functional wellbeing. A scale from 0 to 4 is used with 0= not at all, 1= a little bit, 2=somewhat, 3=quite a bit, 4=very much.

Time frame: Screening and Week 8

Life quality in children

PEDS-QL for paediatric patients (\<18 years) at Screening and Week 8 to evaluate life quality in children. The patients and /or their parents have to answer questions about pain and hurt, fatigue and sleep, nausea, worry, Nutrition, thinking and communication. A scale from 0 to 4 is used with 0=never a Problem, 1=almost never a problem, 2= sometimes a problem, 3=often a problem, 4= almost always a problem.

Time frame: Screening and Week 8

Effect on the patient's T-cell phenotype in vivo

T-cell phenotyping, samples taken at Screening, Day 0 and each visit from Day 7 to Week 15 after treatment.

Time frame: Screening until Week 15

Effect on the patient's number of expanded T cells

Analysis of virus-specific T cells: frequencies of in vivo expanded virus-specific T cells in peripheral blood samples taken at Screening, Day 0, Day 7 to Week 15 after treatment.

Time frame: Screening until Week 15

Quality of the IMP and performance of the CliniMACS® Prodigy

Assessment of the cellular composition, in particular the percentage of IFN-gamma+ cells, in the IMP.

Time frame: Before IMP release (between Screening and Day 0)

Evaluation of the drop-out rate

Drop-out rate at Day 0 and reasons for drop-out.

Time frame: at Day 0 (planned treatment day)

Time from inclusion to administration of the IMP

Number of days from Screening to Day 0 (day of IMP transfer) to evaluate the required time frame.

Time frame: Screening until Day 0 (treatment day)

Adverse events

Documentation of incidence, severity and type of adverse events from Day 0 to Week 8 and serious adverse events throughout the study to evaluate safety.

Time frame: 15 weeks

Physical examination

Physical examinations will be conducted to identify possible clinically significant pathologies. These findings will be recorded at each visit. The Karnofsky/Lansky index will be included in the physical examination at Screening and at Week 8 only.